Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Literature DB >> 27877092

Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Jonathan Wagner¹, Susan M Abdel-Rahman².

Abstract

Increasingly, children and adolescents with dyslipidemia qualify for pharmacologic intervention. As they are for adults, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are the mainstay of pediatric dyslipidemia treatment when lifestyle modifications have failed. Despite the overall success of these drugs, the magnitude of variability in dose-exposure-response profiles contributes to adverse events and treatment failure. In children, the cause of treatment failures remains unclear. This review describes the updated guidelines for screening and management of pediatric dyslipidemia and statin disposition pathway to assist the provider in recognizing scenarios where alterations in dosage may be warranted to meet patients' specific needs.

Entities: Disease Species

Keywords: atorvastatin; dyslipidemia; fluvastatin; lovastatin; pediatrics; pharmacogenomics; pharmacokinetics; pravastatin; rosuvastatin; simvastatin; statin

Year: 2016 PMID： 27877092 PMCID： PMC5103646 DOI： 10.5863/1551-6776-21.5.380

Source DB: PubMed Journal: J Pediatr Pharmacol Ther ISSN： 1551-6776

237 in total

1. Use of statins for dyslipidemia in the pediatric population.

Authors: Lea S Eiland; Paige K Luttrell
Journal: J Pediatr Pharmacol Ther Date: 2010-07

2. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

Authors: Mikko Niemi; Marja K Pasanen; Pertti J Neuvonen
Journal: Clin Pharmacol Ther Date: 2006-10 Impact factor: 6.875

3. Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

Authors: L E Schanberg; C Sandborg; H X Barnhart; S P Ardoin; E Yow; G W Evans; K L Mieszkalski; N T Ilowite; A Eberhard; L F Imundo; Y Kimura; E von Scheven; E Silverman; S L Bowyer; M Punaro; N G Singer; D D Sherry; D McCurdy; M Klein-Gitelman; C Wallace; R Silver; L Wagner-Weiner; G C Higgins; H I Brunner; L Jung; J B Soep; A M Reed; J Provenzale; S D Thompson
Journal: Arthritis Rheum Date: 2012-01

4. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

Authors: Manthena V Varma; Charles J Rotter; Jonathan Chupka; Kevin M Whalen; David B Duignan; Bo Feng; John Litchfield; Theunis C Goosen; Ayman F El-Kattan
Journal: Mol Pharm Date: 2011-07-11 Impact factor: 4.939

5. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia.

Authors: Kuan Gandelman; Paul Glue; Rachel Laskey; Jonathan Jones; Robert LaBadie; Leiv Ose
Journal: Pediatr Cardiol Date: 2011-01-23 Impact factor: 1.655

6. Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials.

Authors: L Gao; F-L Zhao; S-C Li
Journal: Exp Clin Endocrinol Diabetes Date: 2012-05-25 Impact factor: 2.949

Review 7. NK-104: a novel synthetic HMG-CoA reductase inhibitor.

Authors: K Kajinami; H Mabuchi; Y Saito
Journal: Expert Opin Investig Drugs Date: 2000-11 Impact factor: 6.206

8. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients.

Authors: A Asberg; A Hartmann; E Fjeldså; S Bergan; H Holdaas
Journal: Am J Transplant Date: 2001-11 Impact factor: 8.086

9. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.

Authors: G Fauler; C Abletshauser; W Erwa; R Löser; K Witschital; W März
Journal: Int J Clin Pharmacol Ther Date: 2007-06 Impact factor: 1.366

Pediatric Statin Administration: Navigating a Frontier with Limited Data.

1. Use of statins for dyslipidemia in the pediatric population.

2. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.

3. Use of atorvastatin in systemic lupus erythematosus in children and adolescents.

4. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

5. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia.

6. Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials.

Review 7. NK-104: a novel synthetic HMG-CoA reductase inhibitor.

8. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients.

9. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.

10. Early statin therapy restores endothelial function in children with familial hypercholesterolemia.

1. Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.

2. Ontogeny-related pharmacogene changes in the pediatric liver transcriptome.

3. Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.

Review 4. Management of dyslipidemia in pediatric renal transplant recipients.